To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA

Inclusion Criteria:

1. Generally healthy adults aged 18 years or older at the time of enrollment andwith a body mass index (BMI) of ≤30 kg/m2

• Completion of a prior COVID-19 primary vaccination course or booster (anycommercially available within the study country) at least 3 months prior toenrollment OR recent clinically documented SARS-CoV-2 infection (by polymerase chainreaction [PCR] or antibody test) in the past three months but not within one monthfrom enrollment.

• Willing to refrain from receiving an authorized COVID-19 booster dose until at least 90 days post IP administration.

• Female participants of child-bearing potential must have practiced adequatecontraception for 30 days before IP injection, have a negative pregnancy test on theday of IP injection, and agree to continue adequate contraception until 180 daysafter IP injection. (Please refer to Section 10.44 for the definition ofchildbearing potential and adequate contraception).

• Male participants must agree to continue adequate contraception until 180 days afterIP injection.

• Able to consent to participate in the study and signed an Informed Consent Form (ICF).

• Able and willing to complete all the scheduled study procedures during the wholestudy period (approximately 6.5 months).

• Generally, in good health, as determined by a review of medical history and aphysical examination within 14 days prior to IP injection.

Exclusion Criteria:

1. History of anaphylaxis to key ingredients within the vaccine. 2. History ofseizure disorder, encephalopathy, or psychosis. 3. Female participant ispregnant (positive urine pregnancy test), lactating, or plans to becomepregnant during the 180 days of enrollment. 4. Positive test result for humanimmunodeficiency virus (HIV) or hepatitis B and C at Screening (test to beperformed at the discretion of the investigator based on medical history orphysical examination). 5. Positive result of lateral flow test for SARS-COV-2on Day 0. 6. Laboratory (hematological and biochemistry) examination that isout of normal range or greater than a Grade 2 abnormality. Grade 1abnormalities will not be exclusionary if considered not clinically significantby the investigator. Laboratory tests include: complete blood count (CBC),prothrombin time (PT), partial thromboplastin time (PTT), alanineaminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (T Bil), creatinine (CR), lipase, and blood glucose atscreening. 7. Transient mild laboratory abnormalities may be rescreened once,and the participant will be excluded if the laboratory repeat test is abnormalas per local laboratory normal values and the investigator's assessment. 8.Presents with any acute febrile disease (oral temperature ≥37.5°C [99.5oF]) oractive infectious disease within 48 hours prior to IP injection. 9. Unstableconcomitant underlying conditions. Note: Stable condition defined as: theparticipant is appropriately managed on consistent disease management; forexample, participants with well-controlled hypertension, adult-onset diabetes,benign prostate hypertrophy, or hypothyroid disease will be eligible forenrollment. The treatment regimen should be stable for at least 3 months priorto entering the study. Once IP treatment has started, the patient must bewilling to maintain all aspects of the treatment regimen and forgo any electivechanges in medication or management. Emergency changes in medication ormanagement would be captured as an AE. 10. History of Guillain-Barre Syndromeor degenerative neurological disorders; a history of autoimmune, inflammatorydisease or potential immune-mediated diseases (pIMD), or any condition that mayput the participant at increased risk of safety events. 11. History of seriouscardiovascular diseases, such as arrhythmia, conduction block, history ofmyocardial infarction, and severe hypertension not controlled with medication.

2. History of immunodeficiency, asplenia, or functional asplenia. 13. Historyof platelet disorder or other bleeding disorder that may cause contraindicationfor IM injection. 14. Heavy smoker (>10 cigarettes per day), vaper (>1 mL ofe-liquid per day), or cannabis user ([near] daily use). Smokers have to agreeto use the same cigarette brand throughout the study.

3. History or diagnosis of coagulopathies. 16. Prior receipt of immunosuppressivemedication, cytotoxic therapy, or systemic corticosteroids within 6 monthsbefore Day 0. 17. Recent receipt of blood products within 4 months before Day

4. 18. Administration of other investigational drugs within 3 months before Day 0 or planned use during the study period. 19. Currently has or a history of anycondition that, in the opinion of the investigator, may interfere with theparticipant's compliance, evaluation of study objectives, or informed consentprocess (i.e., medical, psychological, social, or other conditions).